Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary ...

Eli Lilly's stock surges as its investigational oral GLP-1 pill, orforglipron, achieves the primary and key secondary goals in the first late-stage study for adults with T2D.

A new GLP-1 drug, orforglipron, comes in pill form and appears to be roughly as effective as injected drugs like Ozempic.

Eli Lilly’s shares shot up 11% pre-market on Thursday after orforglipron became the first small-molecule GLP-1 drug to ace a ...

Eli Lilly and Company has announced positive topline Phase 3 results from Achieve-1, evaluating the safety and efficacy of ...

The Phase Ib study investigated the half-life of three ultra-long-acting SQ injection formulations of ASC30 (100 mg, single injection), a small molecule GLP-1 receptor (GLP-1R) agonist ...

According to an official statement from Eli Lilly and Company, "Orforglipron is the first oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water ...

Rival companies trying to develop oral weight-loss candidates include Novo Nordisk, which has an oral formulation of ...

Structure Therapeutics Inc.’s GPCR share price has surged by 29.14%, which has investors questioning if this is right time to sell.

NEW YORK, NY, USA I April 14, 2025 I Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral ...